Houston (1)

FLT3 Gene Mutation Negative (1)

FLT3 Internal Tandem Duplication Positive (1)

Recurrent Acute Myeloid Leukemia (1)

Recurrent Chronic Myelomonocytic Leukemia (1)

Recurrent Myelodysplastic Syndrome (1)

Refractory Acute Myeloid Leukemia (1)

Refractory Chronic Myelomonocytic Leukemia (1)

Refractory Myelodysplastic Syndrome (1)

Active, not recruiting (1)

phase 1/phase 2 (1)

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

azacitidine (1)

cytarabine (1)

pharmacodynamic study (1)

quizartinib (1)

drug (1)

other (1)

Other (1)

Interventional (1)

flt3 gene mutation negative

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Nov 16, 2022